Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1

Status

Completed 3Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 86Gynecologic 7Tumor-Agnostic 6Breast 6Thoracic 5Genitourinary 5Other hematologic neoplasm 4Dermatologic 4Sarcoma 3Lymphoid 3Plasma cell 2Myeloid 2Head & Neck 2CNS 2Other solid neoplasm 1Classical hematology 1

Conditions

Neoplasms 22Adenocarcinoma 9Neoplasm Metastasis 6Carcinoma, Squamous Cell 2Neoplasms, Unknown Primary 1Neoplasms, Second Primary 1

Interventions

pembrolizumab 34Specimen Handling 26Magnetic Resonance Spectroscopy 26Radiosurgery 25Biopsy 25Gemcitabine 22Nivolumab 21Paclitaxel 18Carboplatin 16Bevacizumab 15Trastuzumab 14Everolimus 12Radiotherapy 11Irinotecan 11trastuzumab deruxtecan 10atezolizumab 10Erlotinib Hydrochloride 10Docetaxel 10Cetuximab 10Capecitabine 10Albumin-Bound Paclitaxel 10130-nm albumin-bound paclitaxel 10Sorafenib 9Ipilimumab 9Cisplatin 9Taxes 8Standard of Care 8Oxaliplatin 8Drug Therapy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Leucovorin × Tumor-Agnostic × Clear all
NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Astellas Pharma Inc

Phase 1 Recruiting
681 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03388190 2026-02-13

METIMMOX

University Hospital, Akershus

Phase 2 Completed
80 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03806309 2025-07-25

TEDOPAM

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Active not recruiting
106 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02625610 2022-06-09

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

EMD Serono

Phase 3 Completed
499 enrolled 22 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT02856867 2017-05-09

MEGAN

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT00507091 2016-08-25

Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

Sanofi

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡